I-Mab logo
I-Mab IMAB

Quarterly report 2025-Q4
added 04-25-2026

report update icon

I-Mab Interest Expense 2011-2026 | IMAB

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.
Includes:
  • Interest on bank loans
  • Interest on corporate bonds
  • Interest on leases
  • Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense I-Mab

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - 722 K 9 K 83.2 M 957 K 2.99 M 11.7 M 5.64 M - - - - - -

All numbers in CNY currency

Indicator range from annual reports

Maximum Minimum Average
83.2 M 9 K 15 M

Interest Expense of other stocks in the Biotechnology industry

Issuer Interest Expense Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
4.66 M - 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
29.5 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-5.79 M - 1.93 % $ 17.4 M usaUSA
Genfit SA Genfit SA
GNFT
4.68 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
1.82 M $ 21.96 -0.68 % $ 3.64 B usaUSA
Allakos Allakos
ALLK
8 K - - $ 28.6 M usaUSA
Advaxis Advaxis
ADXS
28 K - -9.65 % $ 45.9 M usaUSA
AlloVir AlloVir
ALVR
1.44 M - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-5.01 K - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-4 K - - $ 10.1 M usaUSA
Akouos Akouos
AKUS
-1.72 M - 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
2.2 M $ 6.4 4.4 % $ 63.3 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-27 K - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
737 K - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
294 K - -52.27 % $ 4.45 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
23 K $ 21.41 1.9 % $ 1 B usaUSA
Aravive Aravive
ARAV
2.84 M - -13.39 % $ 1.45 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-6 K - -4.8 % $ 255 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-93 K - -2.5 % $ 5.88 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
51 K - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
14.2 M $ 105.46 -0.09 % $ 27.2 B germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-42.6 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.67 M - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
6.55 M $ 4.08 0.25 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
443 K $ 23.26 1.75 % $ 2.96 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
7.16 M - -3.03 % $ 260 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
36.7 M $ 1.44 -5.88 % $ 383 M britainBritain
BioXcel Therapeutics BioXcel Therapeutics
BTAI
-3.52 M $ 1.06 -3.64 % $ 12.9 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
2.9 K - - $ 35.4 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
2 M $ 2.95 -3.28 % $ 296 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
227 K $ 2.91 -1.36 % $ 4.79 M israelIsrael
bluebird bio bluebird bio
BLUE
16.4 M - - $ 546 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
18.9 M - - $ 3.45 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
4.67 M - - $ 3.67 B usaUSA